According to Laimei Pharmaceutical's announcement, Chongqing Laimei Longyu Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for fenelidone approved by the State Drug Administration. The API was approved for domestic production and marketing. The notice is valid until September 9, 2031. Fenelidone is a nonsteroidal selective halocorticoid receptor antagonist, formulated to treat adult patients with chronic kidney disease associated with type 2 diabetes. This approval will help enrich the company's product line and enhance its core competitiveness. There is uncertainty about the subsequent production and sale of drugs.

According to Laimei Pharmaceutical's announcement, Chongqing Laimei Longyu Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for fenelidone approved by the State Drug Administration. The API was approved for domestic production and marketing. The notice is valid until September 9, 2031. Fenelidone is a nonsteroidal selective halocorticoid receptor antagonist, formulated to treat adult patients with chronic kidney disease associated with type 2 diabetes. This approval will help enrich the company's product line and enhance its core competitiveness. There is uncertainty about the subsequent production and sale of drugs.